Printer Friendly

FOREST LABORATORIES ANNOUNCES ACQUISITION OF PREINDUCTION CERVICAL RIPENER

    NEW YORK, Oct. 27 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that it had acquired the exclusive U.S. rights to market a prostaglandin E2 pessary from Pharmasciences, Inc., of Pennsylvania who have licensed the technology from the British Technology Group.  The product is a polymer-based intravaginal device infused with prostaglandin E2 which is used for cervical ripening in the induction of labor.  The pessary is unique in its highly predictable timed release of drug and its retrieval device which permits maximum flexibility in its use.
    Howard Solomon, president of Forest, stated:  "The prostaglandin E2 pessary complements our growing female health care line and can be promoted to obstetricians/gynecologists, along with Monurol(R), our urinary tract infection antibiotic, and our estradiol patch.  All necessary clinical studies on the pessary are nearing completion and a New Drug Application is expected to be filed with the FDA within the next few months."
    -0-             10/27/93
    CONTACT:  Kenneth E. Goodman, vice president - finance of Forest Laboratories, 212-421-7850
    (FRX) CO:  FOREST LABORATORIES, INC.; PHARMASCIENCES, INC. IN:  MTC SU:  TNM ST:  NY,PA


-- NY030 -- X417 10/27/93
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1993
Words:192
Previous Article:DIAGNOSTEK PURCHASES HIV AIDS SPECIALTY PHARMACY COMPANY
Next Article:PAGENET TO HOLD VIDEOCONFERENCE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters